All Stories

  1. Perceptions of Cancer Through the Ages—From Hippocratic Oncology to Precision Cancer Medicine

    Article • Biomolecules, October 2024, MDPI AG

    Dr Spyros Retsas

  2. Perceptions of Cancer through the Ages – from Hippocratic Oncology to Precision Cancer Medicine

    Article • September 2024, MDPI AG

    Dr Spyros Retsas

  3. The origins, etymology and meaning of metastasis in the context of cancer.

    Article • ESMO Open, July 2017, BMJ

    Dr Spyros Retsas

  4. Geotherapeutics: the medicinal use of earths, minerals and metals from antiquity to the twenty-first century

    Article • Geological Society London Special Publications, December 2016, Geological Society

    Dr Spyros Retsas

  5. Gods behaving badly

    Article • Journal of Medical Biography, October 2013, SAGE Publications

    Dr Spyros Retsas

  6. Ipilimumab and Vemurafenib in melanoma

    Article • Journal of the Royal Society of Medicine, June 2011, SAGE Publications

    Dr Spyros Retsas

  7. Medical experiments in antiquity

    Article • The Lancet, August 2010, Elsevier

    Dr Spyros Retsas

  8. Alexander the Great and his interest in medicine

    Article • Journal of Medical Biography, August 2009, SAGE Publications

    Dr Spyros Retsas

  9. Adjuvant vindesine in metastatic melanoma

    Article • Melanoma Research, April 2009, Wolters Kluwer Health

    Dr Spyros Retsas

  10. Heredopathia atactica polyneuritiformis: Refsum's disease

    Article • Acta Neurologica Scandinavica, January 2009, Wiley

    Dr Spyros Retsas

  11. Reflecting on the 2001 American Joint Committee on Cancer Staging System for Melanoma

    Article • Seminars in Oncology, December 2007, Elsevier

    Dr Spyros Retsas

  12. Sentinel node biopsy confers no added protection to patients with melanoma

    Article • Journal of the Royal Society of Medicine, August 2007, SAGE Publications

    Dr Spyros Retsas

  13. Sentinel node biopsy confers no added protection to patients with melanoma

    Article • Journal of the Royal Society of Medicine, August 2007, SAGE Publications

    Dr Spyros Retsas

  14. INV 9 Prognostic factors of cutaneous melanoma and the latest staging system of the American Joint Committee on Cancer (AJCC): validation in a cohort of 1284 patients from a single institution

    Article • Melanoma Research, February 2007, Wolters Kluwer Health

    Dr Spyros Retsas

  15. Integration of gamma knife surgery in the management of cerebral metastases from melanoma

    Article • Melanoma Research, February 2006, Wolters Kluwer Health

    Dr Spyros Retsas

  16. In Reply:

    Article • Journal of Clinical Oncology, July 2005, American Society of Clinical Oncology (ASCO)

    Dr Spyros Retsas

  17. Cutaneous melanoma

    Article • The Lancet, June 2005, Elsevier

    Dr Spyros Retsas

  18. Cutaneous melanoma

    Article • The Lancet, June 2005, Elsevier

    Dr Spyros Retsas

  19. Randomised clinical trials in Cancer Research

    Article • Journal of Clinical Oncology, December 2004, American Society of Clinical Oncology (ASCO)

    Dr Spyros Retsas

  20. 12 Systemic treatment of metastatic melanoma: current options

    Article • Melanoma Research, August 2004, Wolters Kluwer Health

    Dr Spyros Retsas

  21. can viruses cause melanoma?

    Article • Melanoma Research, August 2004, Wolters Kluwer Health

    Dr Spyros Retsas

  22. P-13 Serum HER-2/neu concentrations in metastatic melanoma

    Article • Melanoma Research, August 2004, Wolters Kluwer Health

    Dr Spyros Retsas

  23. Report on the 5th International Conference on the Adjuvant Therapy of Malignant Melanoma held in Athens, Greece, 18–20 March, 2004

    Article • Melanoma Research, August 2004, Wolters Kluwer Health

    Dr Spyros Retsas

  24. Systemic Treatments For Metastatic Melanoma

    Article • Melanoma Research, April 2004, Wolters Kluwer Health

    Dr Spyros Retsas

  25. The CDKN2A tumour suppressor gene

    Article • Melanoma Research, December 2002, Wolters Kluwer Health

    Dr Spyros Retsas

  26. Report on the 4th International Conference on the Adjuvant Therapy of Malignant Melanoma held at the Royal College of Physicians, London, UK, 15–16 March 2002

    Article • Melanoma Research, June 2002, Wolters Kluwer Health

    Dr Spyros Retsas

  27. Overexpression of HER-2 in thick melanoma

    Article • Melanoma Research, April 2002, Wolters Kluwer Health

    Dr Spyros Retsas

  28. Prognostic factors of cutaneous melanoma and a new staging system proposed by the American Joint Committee on Cancer (AJCC)

    Article • European Journal of Cancer, March 2002, Elsevier

    Dr Spyros Retsas

  29. Adjuvant therapy of malignant melanoma: is there a choice?

    Article • Critical Reviews in Oncology/Hematology, November 2001, Elsevier

    Dr Spyros Retsas

  30. Prognostic factors in therapeutic lymphadenectomy in melanoma

    Article • Melanoma Research, June 2001, Wolters Kluwer Health

    Dr Spyros Retsas

  31. What is the Optimal Therapy of Brain Metastases?

    Article • Clinical Oncology, April 2001, Elsevier

    Dr Spyros Retsas

  32. What is the Optimal Therapy of Brain Metastases?

    Article • Clinical Oncology, March 2001, Springer Science + Business Media

    Dr Spyros Retsas

  33. Serum S100β Protein as a Marker of Disease Activity in Patients with Malignant Melanoma

    Article • Cancer Immunology Immunotherapy, January 2001, Springer Science + Business Media

    Dr Spyros Retsas

  34. In Vitro Cytotoxicity of Norviburtinal and Isopinnatal from Kigelia pinnata Against Cancer Cell Lines

    Article • Planta Medica, December 2000, Thieme Publishing Group

    Dr Spyros Retsas

  35. Oxaliplatin is active in vitro against human melanoma cell lines: comparison with cisplatin and carboplatin

    Article • Anti-Cancer Drugs, November 2000, Wolters Kluwer Health

    Dr Spyros Retsas

  36. Melanoma and additional primary cancers

    Article • Melanoma Research, April 2000, Wolters Kluwer Health

    Dr Spyros Retsas

  37. Melanoma and additional primary cancers

    Article • Melanoma Research, April 2000, Wolters Kluwer Health

    Dr Spyros Retsas

  38. Detection of tyrosinase mRNA by RT-PCR in the peripheral blood of patients with advanced metastatic melanoma

    Article • Melanoma Research, August 1999, Wolters Kluwer Health

    Dr Spyros Retsas

  39. 9 Melanoma and additional primary cancers

    Article • Melanoma Research, June 1999, Wolters Kluwer Health

    Dr Spyros Retsas

  40. O10 Serum S-100 protein as a marker of disease activity in malignant melanoma (MM)

    Article • Melanoma Research, June 1999, Wolters Kluwer Health

    Dr Spyros Retsas

  41. P29 Detection of tyrosinase mRNA by RT-PCR in peripheral blood of patients with melanoma

    Article • Melanoma Research, June 1999, Wolters Kluwer Health

    Dr Spyros Retsas

  42. 24 Adjuvant therapy for malignant melanoma. Is there a choice?

    Article • Melanoma Research, June 1999, Wolters Kluwer Health

    Dr Spyros Retsas

  43. Sentinel-Lymph-Node Biopsy

    Article • New England Journal of Medicine, January 1999, New England Journal of Medicine (NEJM/MMS)

    Dr Spyros Retsas

  44. Adjuvant therapy of melanoma

    Article • The Lancet, August 1998, Elsevier

    Dr Spyros Retsas

  45. Dissection of regional lymph nodes in cutaneous melanoma

    Article • The Lancet, June 1998, Elsevier

    Dr Spyros Retsas

  46. 2nd International Conference on the AdjuvantTherapy of Malignant Melanoma London, UK, 14–15 March, 1997

    Article • Melanoma Research, April 1997, Wolters Kluwer Health

    Dr Spyros Retsas

  47. 7 Adjuvant therapy of malignant melanoma; the unreachable goal?

    Article • Melanoma Research, April 1997, Wolters Kluwer Health

    Dr Spyros Retsas

  48. 21 Activity of Taxanes combined with Vinorelbine in disseminated malignant melanoma

    Article • Melanoma Research, April 1997, Wolters Kluwer Health

    Dr Spyros Retsas

  49. 22 Adjuvant Vindesine in malignant melanoma (MM); 20 years on

    Article • Melanoma Research, April 1997, Wolters Kluwer Health

    Dr Spyros Retsas

  50. 45 Activity of Docetaxel (D) and Vinorelbine (V) in vitro against human melanoma cell lines

    Article • Melanoma Research, April 1997, Wolters Kluwer Health

    Dr Spyros Retsas

  51. In vitro synergy of paclitaxel (Taxol) and vinorelbine (navelbine) against human melanoma cell lines

    Article • European Journal of Cancer, March 1997, Elsevier

    Dr Spyros Retsas

  52. Systemic treatment of malignant melanoma: grade is as important as stage

    Article • Clinical and Experimental Dermatology, March 1997, Wiley

    Dr Spyros Retsas

  53. Systemic treatment of malignant melanoma: grade is as important as stage

    Article • Clinical and Experimental Dermatology, March 1997, Wiley

    Dr Spyros Retsas

  54. The combination of paclitaxel with cisplatin exhibits antagonism in vitro against human melanoma

    Article • Anti-Cancer Drugs, June 1996, Wolters Kluwer Health

    Dr Spyros Retsas

  55. Adjuvant interferon alfa-2b for high-risk melanoma.

    Article • Journal of Clinical Oncology, June 1996, American Society of Clinical Oncology (ASCO)

    Dr Spyros Retsas

  56. Fertility after prolonged chemotherapy for metastatic malignant disease

    Article • The Lancet, March 1996, Elsevier

    Dr Spyros Retsas

  57. Taxol and vinorelbine

    Article • Anti-Cancer Drugs, March 1996, Wolters Kluwer Health

    Dr Spyros Retsas

  58. Cutaneous Melanoma-Associated Retinopathy

    Article • Journal of Neuro-Ophthalmology, March 1996, Wolters Kluwer Health

    Dr Spyros Retsas

  59. Taxol and vinorelbine: a new active combination for disseminated malignant melanoma

    Article • Anti-Cancer Drugs, February 1996, Wolters Kluwer Health

    Dr Spyros Retsas

  60. Malignant melanoma co-existing with sarcoidosis: implications for prognosis and management

    Article • Melanoma Research, February 1996, Wolters Kluwer Health

    Dr Spyros Retsas

  61. 1st International Conference on the Adjuvant Therapy of Malignant Melanoma

    Article • Melanoma Research, December 1995, Wolters Kluwer Health

    Dr Spyros Retsas

  62. 5 Clinical observations on the biology of malignant melanoma

    Article • Melanoma Research, December 1995, Wolters Kluwer Health

    Dr Spyros Retsas

  63. 16 Clinical and histological involvement of regional lymph nodes in malignant melanoma

    Article • Melanoma Research, December 1995, Wolters Kluwer Health

    Dr Spyros Retsas

  64. Cutaneous Melanoma-associated Retinopathy

    Article • Ophthalmology, November 1994, Elsevier

    Dr Spyros Retsas

  65. Activity of Extracts ofKigelia pinnataAgainst Melanoma and Renal Carcinoma Cell Lines

    Article • Planta Medica, October 1994, Thieme Publishing Group

    Dr Spyros Retsas

  66. Pharmaceuticals from plants

    Article • The Lancet, July 1994, Elsevier

    Dr Spyros Retsas

  67. Adjuvant interferon in melanoma

    Article • The Lancet, June 1994, Elsevier

    Dr Spyros Retsas

  68. Clinical and histologic involvement of regional lymph nodes in malignant melanoma. Adjuvant vindesine improves survival

    Article • Cancer, April 1994, Wiley

    Dr Spyros Retsas

  69. Antiproliferative activity of vinorelbine (Navelbine) against six human melanoma cell lines

    Article • Journal of Cancer Research and Clinical Oncology, April 1992, Springer Science + Business Media

    Dr Spyros Retsas

  70. Metastasis to the penis from malignant melanoma: Case report and review of the literature

    Article • Clinical Oncology, January 1992, Elsevier

    Dr Spyros Retsas

  71. α-Interferons: Impact on survival of patients with renal cell carcinoma

    Article • Clinical Oncology, September 1991, Elsevier

    Dr Spyros Retsas

  72. Ondansetron; further progress in the prevention of nausea and vomiting induced by anti-cancer chemotherapy

    Article • Clinical Oncology, May 1991, Elsevier

    Dr Spyros Retsas

  73. α-interferons: Impact on survival of patients with renal cell carcinoma

    Article • Clinical Oncology, January 1991, Elsevier

    Dr Spyros Retsas

  74. Intralesional tumour necrosis factor combined with interferon gamma in metastatic melanoma.

    Article • BMJ, May 1989, BMJ

    Dr Spyros Retsas

  75. Central nervous system lnvolvement in malignant melanoma

    Article • Cancer, May 1988, Wiley

    Dr Spyros Retsas

  76. EARLY OR LOW-GRADE MELANOMA?

    Article • The Lancet, August 1987, Elsevier

    Dr Spyros Retsas

  77. Missed malignant melanoma

    Article • BMJ, July 1986, BMJ

    Dr Spyros Retsas

  78. Missed malignant melanoma

    Article • BMJ, May 1986, BMJ

    Dr Spyros Retsas

  79. Missed malignant melanoma

    Article • BMJ, May 1986, BMJ

    Dr Spyros Retsas

  80. Missed malignant melanoma

    Article • BMJ, May 1986, BMJ

    Dr Spyros Retsas

  81. Malignant Melanoma: Prolonged Survival after Cerebral Metastasis

    Article • Journal of the Royal Society of Medicine, September 1985, SAGE Publications

    Dr Spyros Retsas

  82. Antiemetic prophylaxis with high dose metoclopramide or lorazepam in vomiting induced by chemotherapy.

    Article • BMJ, June 1984, BMJ

    Dr Spyros Retsas

  83. Treatment of refractory malignant neoplasms with ifosfamide as single agent and in combination chemotherapy

    Article • Cancer Treatment Reviews, September 1983, Elsevier

    Dr Spyros Retsas

  84. Sun beds and melanoma.

    Article • BMJ, March 1983, BMJ

    Dr Spyros Retsas

  85. Pigment streaks in the nail plate due to secondary malignant melanoma

    Article • British Journal of Dermatology, March 1983, Wiley

    Dr Spyros Retsas

  86. Evaluation of human lymphoblastoid interferon in advanced malignant melanoma

    Article • Cancer, January 1983, Wiley

    Dr Spyros Retsas

  87. Updated results of vindesine as a single agent in the therapy of advanced malignant melanoma

    Article • Cancer Treatment Reviews, September 1980, Elsevier

    Dr Spyros Retsas

  88. HEREDOPATHIA ATACTICA POLYNEURITIFORMIS (REFSUM'S DISEASE) TREATED BY DIET AND PLASMA-EXCHANGE

    Article • The Lancet, March 1979, Elsevier

    Dr Spyros Retsas

  89. Vindesine as a single agent in the treatment of advanced malignant melanoma

    Article • Cancer Chemotherapy and Pharmacology, January 1979, Springer Science + Business Media

    Dr Spyros Retsas

  90. Vinca Alkaloids and Platelets

    Article • New England Journal of Medicine, August 1978, New England Journal of Medicine (NEJM/MMS)

    Dr Spyros Retsas

  91. AGRANULOCYTOSIS IN BREAST-CANCER PATIENTS TREATED WITH LEVAMISOLE

    Article • The Lancet, August 1978, Elsevier

    Dr Spyros Retsas

  92. Symptom relief with levamisole in stage IV Hodgkin's disease.

    Article • BMJ, June 1977, BMJ

    Dr Spyros Retsas

  93. Successful bone marrow transplant for Fanconi's anaemia.

    Article • BMJ, February 1977, BMJ

    Dr Spyros Retsas

  94. Insulin abuse by a drug addict.

    Article • BMJ, December 1972, BMJ

    Dr Spyros Retsas